Correct ITT. Both non-memantine cohorts in the 20 ug and 40 ug doses at all 4 test dates showed improvement as well. 7 of 8 placebo showed worse test scores. That's what Alkon referred to as "black and white" data. Essentially the entire group were super responders regardless of any genetic issues. We just remove one type of medication from the equation and bingo there it was . In less than 12 months we'll know in a bigger population if results can be repeated. That's the chance we take as investors.
If anyone can find a more statistically significant result from a P1,2,3, or 4 trial currently being run...even if in a subgroup, even if in another country, then I would like to see it. Our hypothesis isn't slowing decline, its increasing SIB scores but I'll take any statistically significant comparisons.
News 
Market Data 
Discover 
AI
